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Abstract: Clostridium perfringens enterotoxin (CPE), a major cause of food poisoning, 
forms physical pores in the plasma membrane of intestinal epithelial cells. The ability of 
CPE to recognize the epithelium is due to the C-terminal binding domain, which binds to a 
specific motif on the second extracellular loop of tight junction proteins known as claudins. 
The interaction between claudins and CPE plays a key role in mediating CPE toxicity by 
facilitating  pore  formation  and  by  promoting  tight  junction  disassembly.  Recently,  the 
ability of CPE to distinguish between specific claudins has been used to develop tools for 
studying roles for claudins in epithelial barrier function. Moreover, the high affinity of CPE 
to selected claudins makes CPE a useful platform for targeted drug delivery to tumors 
expressing these claudins. 
Keywords: Clostridium perfringens; claudin; tight junction; intestinal epithelium; cancer 
therapeutics; acute lung injury 
 
1. Introduction 
Clostridium perfringens is a rod-shaped, Gram-positive, anaerobic bacterium, which is responsible 
for a significant fraction of food borne disease [1,2]. There are five subclasses of C. perfringens, which 
are  classified  based  on  the  relative  expression  of  alpha,  beta,  epsilon,  and  iota  toxin.  Of  these 
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subclasses,  a  fraction  of  subclass  A  clinical  isolates  produce  a  35  kDa  polypeptide  known  as 
C. perfringens  enterotoxin  (CPE)  [3].  Although  CPE  is  not  required  for  intestinal  pathogenicity, 
subclasses of C. perfringens that express CPE use this protein to exacerbate the pathogen's effects on 
intestinal epithelia. The increased pathogenicity is due to the ability of CPE to specifically interact with 
a subclass of tight junction proteins, known as claudins [4–6]. Although there are over two dozen 
different claudins, CPE has been shown to interact with claudin-3, -4, -5, -6, -7, -8, -9 and -14 to 
varying degrees, and does not recognize other claudins. As a result, CPE has emerged as a tool being 
used to elucidate roles for claudins in epithelial barrier function. In addition, CPE-based agents are 
being tested for use as a targeted therapeutic, most notably as anti-tumor drugs. 
2. CPE Receptors Are Claudin Family Tight Junction Proteins 
Fibroblasts  lack  the  ability  to  bind  CPE  and  are  resistant  to  CPE-mediated  cell  death.  Thus, 
fibroblasts were used to screen a cDNA library for constructs which confer sensitivity to CPE toxicity. 
Two high affinity CPE transmembrane protein receptors (CPE-R and RVP-1) were discovered using 
this approach [7,8]. It was only a few years later that Morita et al. [9] revealed CPE-R and RVP-1 to be 
the  tight  junction  proteins  claudin-4  and  claudin-3,  respectively.  This  finding  added  CPE  to  the 
growing  list  of  proteins produced by pathogens that use different classes of host junction proteins as 
receptors [10–12].  
Figure  1.  Protein  components  of  tight  junctions  between  polarized  epithelial  cells.  
(A)  Based on freeze fracture electron microscopy, tight junctions appear as a series of 
beaded  strands  in  the  plasma  membrane  at  cell-cell  contact  sites,  modified  from  [13];  
(B) Tight junctions consist of several proteins, including transmembrane proteins linked to 
the actin cytoskeleton by scaffold proteins. Of these transmembrane proteins, claudins are 
the  primary  structural  determinants  of  paracellular  permeability;  (C) Claudins  span  the 
bilayer  four  times,  with  N-  and  C-  termini  oriented  towards  the  cytosol  and  have  two 
extracellular loop (EL) domains. 
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Claudins are 20–27 kDa transmembrane proteins that span the membrane bilayer four times (Figure 1). 
The  N-  and  C-  termini  are  oriented  towards  the  cytoplasm  and  there  are  two  extracellular  loop 
domains,  both  of  which  mediate  interactions  with  other  claudins  [14–16].  Claudins  are  a  major 
constituent of tight junctions, which are cell-cell contact sites between polarized epithelial cells that 
serve to regulate the movement of ions and molecules between cells. In addition to claudins, tight 
junctions  also  contain  other  proteins,  including  transmembrane  proteins  such  as  occludin  and 
cytoplasmic scaffold proteins, mainly zonula occludens (ZO)-1 and -2, which tether claudins to the 
cytoskeleton and are required to maintain paracellular permeability [17–19].  
Although several different types of protein are needed to regulate tight junctions, it is primarily the 
profile of claudin expression which enables tight junctions to have unique permeability by forming 
what are effectively paracellular channels [20]. Paracellular ion selectivity is established by structural 
motifs  in  the  two  claudin  extracellular  loop  domains,  primarily  charged  amino  acids  in  the  first 
extracellular loop (EL1) [15,21–24]. By contrast, the smaller second extracellular loop (EL2) contains 
~25 amino acids and helps narrow the paracellular gap and plays a role in regulating heteromeric 
claudin-claudin interactions [25]. In addition, the claudin EL2 domain is the site where CPE binds to 
specific claudins (see below). 
3. Mechanism of Action for CPE Toxicity 
After ingestion of contaminated food, C. perfringens passes from the stomach to the small intestine 
where it multiplies and sporulates. During sporulation, CPE is expressed and accumulates within the 
bacterium until it is discharged when the sporulating cells lyse. Upon release into the intestinal lumen, 
CPE binds to intestinal epithelial cells and initiates a cascade of events leading to cell death [7,8,26]. 
Figure  2.  Sequential  intermediates  in  CPE:epithelial  cell  membrane  interactions.  CPE 
initially binds directly to claudins at the plasma membrane, most typically claudin-3 or 
claudin-4  on  intestinal  epithelium.  The  initial  small  CPE/claudin  complexes  may  also 
include  other  claudins,  e.g., claudin-1, via an indirect interaction. Six small complexes 
oligomerize  to  form  a  hexameric complex (CH-1) that forms pores which compromise 
plasma membrane integrity. CH-1 complexes eventually incorporate occludin and disrupt 
epithelial tight junctions resulting in a breakdown of barrier function. 
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There are three major biochemically isolatable complexes that represent the sequence of interaction 
of  CPE  with  cell  tight  junction  proteins,  a  small  complex  containing  CPE  and  claudins  which 
subsequently oligomerizes and then incorporates occludin [27]. CPE initially binds to claudins to form 
a small 90 kD complex (Figure 2), which itself is insufficient for cytotoxicity [26]. Interestingly, when 
formed by human CaCo2 colon epithelial cells, the small CPE complex contains claudin-1 in addition 
to claudin-3 and/or claudin-4, despite the fact that CPE does not directly bind to claudin-1 [28,29]. 
Thus, the presence of claudin-1 in the complex is more likely to be due to an interaction with claudin-3 
and/or claudin-4, rather than a direct interaction with CPE. In addition to claudin-1, it is likely that 
other claudins expressed by intestinal epithelial cells can also associate with the small CPE/claudin 
complex.  In  fact,  claudin-5  has  been  isolated  from  CPE-affinity  columns  using  normal  rat 
cholangiocytes as a starting material, which could be enhanced by an indirect interaction via other 
claudins [30]. Based on apparent size, the small CPE/claudin complex contains one molecule of CPE 
(35 kD) and two claudin molecules (2 × 22 kD = 44 kD). The stoichiometry of the small CPE-claudin 
complex is intriguing in light of current models where claudins stably oligomerize as hexamers [31] 
and  suggests  that  CPE  either  disrupts  claudin  hexamers  or  it  interacts  with  claudin  monomers  or 
dimers at a step prior to complete claudin oligomerization. In the latter case, this would imply that 
claudin oligomerization is completed at the plasma membrane, perhaps following assembly into tight 
junctions. However, the sequence of claudin assembly remains to be determined [4]. Nonetheless, 
claudin-3 mutants which are unable to heterotypically interact have an increased ability to bind to CPE, 
underscoring that CPE interacts with claudins prior to incorporation to tight junction strands [32]. 
Small CPE/claudin complexes then combine to form a large (~450 kD) complex (CH-1) required 
for cytotoxicity [33]. These hexameric pores increase plasma membrane ion permeability [34] allowing 
calcium influx that induces cell death by apoptosis or oncosis [35,36]. 
A ~25 amino acid hydrophobic hairpin domain of CPE is required to form a beta-barrel pore in the 
plasma membrane [37]. The hairpin domain is similar to domains in other beta-barrel pore forming 
bacterial toxins that oligomerize in complexes ranging from pentamers to octomers [38]. However, 
while these other toxins require cholesterol for membrane binding and pore formation, CPE does not 
[39]. In fact, CPE binding induces claudins to partition away from cholesterol enriched membrane 
microdomains,  thus  contributing  to  the  disruption  of  epithelial  barrier  function.  Whether  claudins 
contribute to CPE pore structure is not known, however, since claudins oligomerize as part of their role 
in tight junction formation, they may be a structural element of the CPE pore. It is interesting to note 
that a C-terminal claudin-4 mutant which lacks the PDZ-binding motif, a domain required for binding 
to ZO-1 and ZO-2 and incorporation into tight junction strands, still supports small complex formation 
and  CPE-mediated  toxicity.  Thus,  tight  junction  scaffold  proteins  are  not  required  for  
CPE-claudin interactions or pore formation [33]. 
CH-1 complexes have also been shown to mature into larger CH-2 complexes containing occludin 
[40]. The interaction of CPE with occludin requires claudins, although a low affinity occludin binding 
site  of  CPE  has  not  been  ruled  out.  Binding  of  CPE  to  claudins  and  occludin  is  associated  with 
internalization of these tight junction proteins, a process that compromises epithelial barrier function 
and therefore contributes to the mechanism of action for CPE toxicity [40]. Consistent with this model, 
internalization  and  subsequent  degradation  of  tight  junction  proteins  is  frequently  associated  with Toxins 2010, 2  
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impaired barrier function [41–43]. It remains to be determined whether CH-2 induces claudin and 
occludin internalization or forms after endocytosis to promote tight junction protein degradation. 
4. Structural Basis and Specificity of CPE-Claudin Interactions 
Further screening of claudins using transfected fibroblasts and/or biochemical approaches was used 
to determine that full length CPE or CPE-derived protein fragments can bind to claudin-6, -7, -8, -9 or -14 
[28,32,44]. Moreover, this analysis confirmed that several claudins were unable to interact with CPE, 
which defined a subset of claudin-family proteins with the capacity to act as CPE receptors. While 
CPE can interact with several different claudins in vitro and in transfected cells, the pathobiology of 
C. Perfringens  depends  upon  the  claudins  expressed  by  intestinal  epithelium  and  accessibility  to 
toxins.  In  addition  to  claudin-3  and  claudin-4,  other  claudins  significantly  expressed  by  intestinal 
epithelium, which can also bind CPE, include claudin-7 and claudin-8 [45,46], however whether these 
or other claudins are involved in disease caused by C. Perfringens is unknown at present. 
Figure 3. Claudin binding motif of CPE. (a) Linear diagram showing the domain structure 
of  CPE, emphasizing the cytotoxic (green) and claudin binding (yellow) domains. Key 
truncation mutants are shown below; (b) Structural models of the C-terminal CPE claudin 
binding domain (CPE194–319) [47] were produced using the Molecular Modeling Database 
(MMDB) [48,49]. Shown from left to right are a ribbon diagram, and space filling models 
indicating amino acid charge or hydrophobicity. The top row shows CPE194–319 with the 
claudin binding motif facing the reader, in the bottom row the protein is rotated 90°. Shown 
in yellow is the claudin binding motif of CPE, which is enriched for hydrophobic amino 
acids. The arrowhead denotes the position of Tyr
306. Below each row is a representation of 
the claudin extracellular loops, EL1 and EL2, where EL2 interacts with CPE. 
 
Structure-function analysis of CPE reveals that it is comprised of an N-terminal cytotoxic domain 
and  a  C-terminal binding domain. Because a truncation mutant lacking the N-terminal half of the 
protein (CPE171–319) did not exhibit cytotoxic effects when applied to sensitive cells, Hanna et al. [50] Toxins 2010, 2  
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concluded that the N-terminal region of CPE was required for toxicity. However, removal of the first 
37 amino acids of the protein increases the cytotoxicity of the molecule [51,52].  
While CPE171–319 is not toxic to cells, this truncated protein retains the capacity to bind to claudins 
[50].  Further  truncation  demonstrated  that  the  last  30  amino  acids  (CPE290–319)  are  sufficient  to 
recognize some claudins [53]. In addition, a synthetic peptide corresponding to these 30 amino acids 
was shown to have competitive binding activity equal to the native toxin [54], even though it lacks the 
cytotoxic  domain  needed  for  cytolysis,  suggesting  that  all  of  the  CPE  receptor-binding  activity  is 
mediated  by  these  residues  [53].  However,  other  motifs might modulate the specificity of claudin 
binding.  For  instance  CPE116–319  binds  to  cells  expressing  claudin-5,  albeit  at  low  affinity,  while 
CPE194–319 does not [32].  
The crystal structure of CPE194–319 shows that it is a nine-strand sandwich with similarities to the 
receptor binding domains of other pore-forming toxins (Figure 3) [47]. Surface electrostatic potential 
modeling  shows  that  these  residues  form  an  acidic  cleft  surrounding  a  hydrophobic  valley  [44]. 
Consistent with a role for hydrophobic residues in stabilizing the interaction of CPE binding with 
claudins, mutating Tyr
306 to Lys, a positively charged residue, completely abolishes claudin binding, 
while mutations to another aromatic residue, Phe, had no effect [55]. While it is possible that the Lys 
substitution destabilizes CPE and causes it to assume an alternative conformation, it does not seem 
likely given that Tyr
306 is located on an intervening surface loop between two beta strands (Figure 3, 
arrowhead). Mutating Tyr
306, Tyr
310, or Tyr
312 to Ala also impairs CPE claudin interactions [44], while 
mutation of Tyr
306 in combination with one of the other two key Tyr residues completely eliminates 
claudin binding. This mutational analysis underscores the significance of bulky hydrophobic amino 
acids for high affinity CPE-claudin binding [56].  
Fujita et al. [28] first demonstrated that CPE binds to claudins via EL2 using fibroblasts transfected 
with claudin-1/-3 chimeras, using sensitivity to CPE toxicity as an assay for binding. A comparable 
analysis also showed that the EL2 domain of claudin-7 was required for CPE-mediated toxicity; further 
refinement of the CPE binding site using point mutants defined a key role for Asn
149 of claudin-4 in 
binding to CPE [44,57].  
The EL2 binding sites of claudins with high affinity for CPE (claudin-4, claudin-3, claudin-7) have 
a calculated pI in the range of 6.4–9.7 and are enriched for amino acids which can interact with acidic 
residues in the cleft region of the claudin binding site of CPE [44]. In further define roles for basic 
residues in CPE-claudin interactions, a double point mutant in the EL2 domain of human claudin-5 
was developed, where Asp
149 was replaced with Asn and Tyr
158 was replaced with Arg. These amino 
acid substitutions increased the calculated pI of the EL2 domain from 4.2 to 9.7 and significantly 
increased the affinity of binding to full length CPE as compared to wild type human claudin-5 [44]. 
Thus, electrostatic interactions between CPE and claudins promote the specificity of binding. 
Using an array of peptides corresponding to the EL2 claudin domains, Winkler et al. [32] quantified 
binding  of  a  GST-CPE116–319  fusion  protein.  This  analysis  was  used  to  identify  a  key  motif, 
NP(V/L)(V/L)(P/A), in the turn region of EL2 as a required sequence needed for claudins to interact 
with CPE (Figure 4) [32]. The EL2 CPE binding motif is usually conserved when comparing human 
and murine claudins (Figure 4). An important exception to this rule is human claudin-8 which does not 
interact with CPE since it lacks the NPLVD motif present in murine claudin-8 [32,44].  Toxins 2010, 2  
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Figure  4.  Extracellular  loop  domains  of  claudins  recognized  by  CPE.  The 
NP(L/V)(L/V)(P/A)  binding  motif  within  EL2  is  highlighted  below.  Note  that  human 
claudin-8 shows significant sequence divergence from murine claudin-8 and is unlikely to 
interact  with  CPE.  *—conserved  between  human  and  murine  claudin,  :—comparable 
amino acid substitution.  
 
By and large, there was good agreement between the ability of GST-CPE116–319 to bind the EL2 
peptide fragment and binding of full length CPE to full length claudins expressed by cells. However, 
the murine claudin-4 EL2 peptide was unable to bind to GST-CPE116–319, despite the ability of the CPE 
peptide to recognize claudin-4 in transfected cells [32,57]. It is noteworthy that the murine claudin-4 
EL2  domain  contains  Met  in  the  third  position  of  the  CPE  binding  motif;  this  Met  residue  may 
destabilize the claudin-4 EL2 peptide and prevent it from attaining a fully native conformation in vitro, 
despite being tolerated in full length claudin-4 expressed by cells. Also, CPE116–319 binds to an EL2 
peptide  from  murine  claudin-3  with  greater  affinity than a murine claudin-7 peptide [32], yet full 
length CPE equivalently recognizes HEK293 cells transfected with either claudin-3 or claudin-7, based 
on cell killing assays [44]. Differences in the affinity of CPE for isolated EL2 domains vs. full length 
claudins  in  situ,  indicates  the  plasticity  of  EL2  conformation  and  underscores  the  need  for  high 
resolution claudin structure determination to fully understand CPE-claudin interactions. 
human Cldn human Cldn human Cldn human Cldn- - - -3         NTIIRDFYNPVVPEAQKREM  3         NTIIRDFYNPVVPEAQKREM  3         NTIIRDFYNPVVPEAQKREM  3         NTIIRDFYNPVVPEAQKREM        
murine Cldn murine Cldn murine Cldn murine Cldn- - - -3        NTIIRDFYNPLVPEAQKREM 3        NTIIRDFYNPLVPEAQKREM 3        NTIIRDFYNPLVPEAQKREM 3        NTIIRDFYNPLVPEAQKREM              
                                                                                                                          **:**         **:**         **:**         **:**               
human Cldn human Cldn human Cldn human Cldn- - - -4       4       4       4                     HNIIQDFYNPLVASGQKREM  HNIIQDFYNPLVASGQKREM  HNIIQDFYNPLVASGQKREM  HNIIQDFYNPLVASGQKREM        
murine Cld murine Cld murine Cld murine Cldn n n n- - - -4        HNVIRDFYNPMV 4        HNVIRDFYNPMV 4        HNVIRDFYNPMV 4        HNVIRDFYNPMVASGQKREM  ASGQKREM  ASGQKREM  ASGQKREM        
                                                                                                                       ** **    ** **    ** **    ** **                                 
human Cldn human Cldn human Cldn human Cldn- - - -5 5 5 5                                          NIVVREFYDPSVPVSQKYEL NIVVREFYDPSVPVSQKYEL NIVVREFYDPSVPVSQKYEL NIVVREFYDPSVPVSQKYEL              
murine Cld murine Cld murine Cld murine Cldn n n n- - - -5         5         5         5        NIVVREFYDPTVPVSQKYEL NIVVREFYDPTVPVSQKYEL NIVVREFYDPTVPVSQKYEL NIVVREFYDPTVPVSQKYEL              
                                                                                                                       **: **: **: **:**    **    **    **                                 
human Cldn human Cldn human Cldn human Cldn- - - -6         HAVIRDFYNPLVAEAQKREL  6         HAVIRDFYNPLVAEAQKREL  6         HAVIRDFYNPLVAEAQKREL  6         HAVIRDFYNPLVAEAQKREL        
murine Cldn murine Cldn murine Cldn murine Cldn- - - -6        HSIIQDFYNP 6        HSIIQDFYNP 6        HSIIQDFYNP 6        HSIIQDFYNPLVADAQKREL LVADAQKREL LVADAQKREL LVADAQKREL              
                                                                                                                          *****         *****         *****         *****               
human Cldn human Cldn human Cldn human Cldn- - - -7         HQIVTDFYNPLIPTNIKYEF  7         HQIVTDFYNPLIPTNIKYEF  7         HQIVTDFYNPLIPTNIKYEF  7         HQIVTDFYNPLIPTNIKYEF        
murine Cldn murine Cldn murine Cldn murine Cldn- - - -7        HQIVTDFYNPLTPMNVKYEF 7        HQIVTDFYNPLTPMNVKYEF 7        HQIVTDFYNPLTPMNVKYEF 7        HQIVTDFYNPLTPMNVKYEF              
                                                                                                                       *** *** *** ***       *       *       *       *                        
human Cldn human Cldn human Cldn human Cldn- - - -8         NAIIRDFYNSIVNVAQKREL  8         NAIIRDFYNSIVNVAQKREL  8         NAIIRDFYNSIVNVAQKREL  8         NAIIRDFYNSIVNVAQKREL        
murine Cldn murine Cldn murine Cldn murine Cldn- - - -8        NSIIRDFY 8        NSIIRDFY 8        NSIIRDFY 8        NSIIRDFYNPLVDVALKREL NPLVDVALKREL NPLVDVALKREL NPLVDVALKREL              
                                                                                                                          * :*          * :*          * :*          * :*                
human Cldn human Cldn human Cldn human Cldn- - - -9         HAIIQDFYNPLVAEALKREL 9         HAIIQDFYNPLVAEALKREL 9         HAIIQDFYNPLVAEALKREL 9         HAIIQDFYNPLVAEALKREL              
murine Cldn murine Cldn murine Cldn murine Cldn- - - -9        HAIIQDFYNPLVAEALKREL 9        HAIIQDFYNPLVAEALKREL 9        HAIIQDFYNPLVAEALKREL 9        HAIIQDFYNPLVAEALKREL              
                                                                                                                          *****         *****         *****         *****               
human Cldn human Cldn human Cldn human Cldn- - - -14        NDVVQNFYNPLLPSGMKFEI  14        NDVVQNFYNPLLPSGMKFEI  14        NDVVQNFYNPLLPSGMKFEI  14        NDVVQNFYNPLLPSGMKFEI        
murine Cldn murine Cldn murine Cldn murine Cldn- - - -14       NDVVQN 14       NDVVQN 14       NDVVQN 14       NDVVQNFYNPLLPSGMKFEI FYNPLLPSGMKFEI FYNPLLPSGMKFEI FYNPLLPSGMKFEI              
                                                                                                                          *****         *****         *****         *****               Toxins 2010, 2  
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5. CPE as a Tool to Study Epithelial Tight Junctions 
The binding of CPE to specific claudins affects the structure of epithelial tight junctions independent 
of its cytotoxic effects [27,29,58]. This property is shared by C-terminal CPE fragments which retain 
the capacity to bind claudins. For instance, Sonoda et al. [29] showed that addition of the CPE184–319 
fragment to the basolateral surface of MDCK I cells selectively removed endogenous claudin 4 from 
tight junctions while largely maintaining claudin-1 localization. Additionally, CPE184–319 treatment led 
to fragmented tight junctions and impaired barrier function, indicating a central role for claudin-4 in 
maintaining MDCK barrier function [29].  
The recent observation that claudin-4 is specifically upregulated in response to acute lung injury led 
to the use of CPE as a tool to identify specific roles for claudin-4 in the injury response [58]. In this 
study, Wray, et al. [58] used a CPE290–319 peptide administered in vivo to mice prior to experimentally 
induced  lung  injury  of  varying  severity.  CPE290–319  administered  in  vivo  significantly  decreased 
claudin-4 content of the lung. Functionally, CPE290–319 dramatically increased bulk alveolar protein 
permeability (leak) in response to severe lung injury, underscoring a role for upregulated claudin-4 in 
protecting the lung from mechanical injury to tight junctions. By contrast, alveolar protein permeability 
was  low  and  largely  unaffected  by  CPE290–319  in  both  the  unstressed  lung  and  lungs  subjected  to 
moderate injury. However, CPE290–319 treatment increased the amount of lung edema in response to 
moderate ventilator induced lung injury and, importantly, diminished the fluid clearance capacity of 
unstressed lungs. Thus, CPE290–319 provided the first in vivo evidence in support of a role for claudins 
in regulating the fine control of fluid balance in the lung [59]. Since lungs express several claudins 
which can interact with CPE, including claudin-3 and -7 [42,60,61], it is possible that changes in the 
mouse  lung  physiology  induced  by  CPE290–319  are  due  to  effects  on  other  claudins.  However,  the 
relatively mild effect of CPE290–319 on unstressed lungs where claudin-4 is not upregulated argues 
against this possibility [58]. 
Beyond identifying roles for claudin-4 in lung physiology, CPE-derived reagents could potentially 
be used to more generally study other aspects of epithelial tight junctions. In order to achieve this, CPE 
variants would need to be designed which preferentially recognize different claudins beyond the subset 
of claudins which already bind CPE. This requires understanding of the molecular basis for CPE-
claudin interactions to a level of depth allowing informed design of new CPE variants. 
6. Targeted Cancer Therapeutics Using CPE  
Histological screens of human tumors have revealed changes in claudin expression associated with 
tumor phenotype [62,63]. Altered claudin expression may lead to abnormal barrier function which, in 
turn, can increase paracellular permeability to ultimately facilitate tumor cell mobility and promote 
nutrient supply to tumor cells [64–67]. Consistent with a reduction in the tight junction barrier, claudin 
expression by tumor cells is frequently down-regulated [62,63,68–77].  
However, there are also several examples where claudin expression is upregulated in many tumors 
including breast, ovarian, and prostate cancers [62,63,78–80]. While this result may seem surprising 
given  the  role  of  claudins  in  tight  junction  integrity,  recent  work  suggests  that  claudins  are  also 
involved in survival and invasion of cancer cells, functions that could be independent of their role as Toxins 2010, 2  
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tight junction proteins [81–83]. Of particular interest, claudin-3 and claudin-4 seem to be generally 
upregulated, particularly in aggressively metatastic tumors [84,85].  
Increased expression of claudin-3 or claudin-4 provides a fortuitous target in these tumors, since 
expression  enables  CPE-based  therapeutic  agents  to  be  developed  as  potential  anti-tumor  agents 
[62,78,86].  Current  preclinical  therapies  include  use  of  both  cytotoxic  CPE  alone  and  C-terminal 
fragments of CPE as a targeting molecule [78,86–91].  
In vitro, CPE treatment of human cancer cell lines and, importantly, breast tumor tissue has been 
shown  to  result  in  cytolysis  and  cell  death  in  a  dose-dependent  manner  [78,86,87].  Using  murine 
xenograft models, the in vivo efficacy of CPE therapy has also been tested. Intra-tumoral injection of 
CPE into pancreatic, breast, and brain cancer tumors significantly impeded tumor growth or caused 
tumor  regression  by  inducing  necrosis  [78,86,88].  Furthermore,  intraperitoneal  injection  of  CPE 
significantly  inhibited  growth  of  explanted  human  ovarian  cancer  in  mice  without  severe 
gastrointestinal side-effects or weight loss [87].  
In addition to utilizing CPE to directly induce cytotoxicity, the non-cytolytic CPE184–319 fragment 
may be effective in the targeted delivery of chemotherapeutic agents. For instance, a fusion protein of 
CPE290–319 and TNF was used to induce cytotoxicity in ovarian cancer cells expressing both claudins-3 
and -4 while remaining non-toxic to cells lacking these proteins [90]. Recently, Ebihara et al. fused 
CPE194–319  to  the  protein  synthesis  inhibitory  factor  (PSIF)  domain  of  Pseudomonas  exotoxin  
(C-CPE-PSIF) and found that this fusion protein was toxic to human breast cancer cells that express 
claudins-3 and -4 [89]. Furthermore, this fusion protein had no effect on L cells expressing exogenous 
claudin-1, claudin-2 or claudin-5 or SK-HEP-1 hepatocytes lacking claudin-4 but expressing other 
claudins, such as claudin-1 [92].  
Two features of C-CPE-PSIF are critical for its mechanism of action. First, by binding to claudins, 
CPE  fusion  proteins  are  internalized  by  endocytosis  [89].  Second,  internalized  C-CPE-PSIF  is 
proteolyzed to release a free PSIF fragment which subsequently crosses the membrane bilayer into the 
cytosol  where  it  kills  cells  by  inhibiting  protein  synthesis  [93].  Importantly,  the  efficacy  of  
C-CPE-PSIF was recently demonstrated in vivo, using several murine tumor metastasis models [94]. In 
this  study,  C-CPE-PSIF  decreased  the  growth  rate  of  subcutaneous  tumors  derived  from  cells 
expressing claudin-4 by 50% and, in the case of 4TI cell derived tumors, the number of metastases 
found in the lungs was almost completely repressed. 
Although the ability of CPE or CPE-based fusion proteins to bind to isolated circulating metastatic 
cells seems straightforward, the mechanisms by which externally applied CPE can successfully target 
solid tumors is less clear. The ability of CPE to cause a breakdown in tight junction barriers is expected 
to contribute to penetration into tumors [29,92,95]. Alternatively, the anti-tumor effect of CPE may be 
limited to a superficial layer of cells in cases where growth is inhibited, but tumors do not decrease in 
mass [86]. It may well be that an adjunct therapeutic, such as the recently discovered iRGD peptide 
[96], will be needed to optimize the efficacy of CPE-based anti-cancer drugs. 
The inherent toxicity of full length CPE represents a significant side effect with the potential to 
reduce  therapeutic  efficacy.  The  route  of  administration  has  a  significant  effect  on  toxicity.  For 
instance, intraperitoneal injection is significantly more toxic than intragastral administration or direct 
injection  into  tumors  [86,78,97].  For  sub-lethal  doses  of  CPE,  both  intraperitoneal  or  intragastral Toxins 2010, 2  
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administration induces a transient spike in cytokine production (mainly IL-6 and IFN-γ) which peaks at 
8 h post treatment [97]. There are also data that CPE acts as a direct mitogen for macrophages and T 
cells in vitro [97,98] and could have superantigen activity [99]. However, other studies demonstrated 
that D-Galactose induced liver injury did not sensitize mice to CPE toxicity [97] and CPE does not act 
as a mitogen for peripheral leukocytes in vitro [100], both of which are hallmarks of superantigenicity. 
These conflicting data are likely to reflect differences in CPE preparations, if contaminants contribute 
to the immune response. From a practical standpoint, some concerns related to CPE-mediated toxicity 
are likely to be ameliorated by replacing the cytotoxic domain of CPE with a domain that has a more 
specific mode of action, such as PSIF, particularly if this prevents a systemic immune response.  
Taken  together,  these  studies  support  the  use  of  CPE-based  pharmaceuticals  as  a  strategy  to 
specifically target tumors with a suitable profile of claudin expression. In general, claudins have great 
potential as targets for cancer therapy, but studies of this family are incomplete. While significant 
progress  has  been  made  in  understanding  the  structural  basis  of  CPE-claudin  interactions,  further 
analysis  could  enable  other  claudin  specific  interacting  molecules  to  be  designed  to  improve  the 
specificity and efficacy of CPE-based therapeutic approaches. 
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